Company Overview

CBD Life Sciences Inc. is a publicly traded company operating in the cannabidiol (CBD) and hemp-derived wellness products industry. The company focuses on the development, marketing, and sale of CBD-based consumer products, including tinctures, edibles, capsules, topical products, and pet-related formulations. Public disclosures and OTC market filings indicate that the company primarily targets the health and wellness consumer segment within the broader alternative wellness and nutraceutical markets. Its business model has centered on direct-to-consumer sales and online retail distribution, with additional emphasis on brand development in the U.S. hemp-derived CBD market.

The company evolved from prior business activities before repositioning toward the CBD and cannabis-adjacent wellness sector following changes in U.S. hemp regulation after the 2018 Farm Bill. CBD Life Sciences has used acquisitions, licensing arrangements, and product branding initiatives to expand its product catalog and market visibility. Publicly available information indicates that the company has pursued a strategy focused on low-overhead product commercialization and investor-facing expansion efforts. Data regarding sustained profitability, material market share, or large-scale distribution partnerships remains limited in publicly available filings and disclosures.

Business Operations

CBD Life Sciences generates revenue primarily through the sale of CBD-infused wellness products under its consumer-facing product lines. Operations have included e-commerce distribution, product marketing, and retail-oriented promotional campaigns. The company has referenced products such as CBD gummies, oils, creams, pain relief formulations, and wellness supplements in public communications. Available disclosures suggest that the company operates with a relatively streamlined organizational structure compared with larger vertically integrated cannabis operators.

The company’s operational footprint appears concentrated in the United States, particularly within the hemp-derived consumer wellness segment. Public filings and announcements have referenced relationships with formulation, manufacturing, and fulfillment partners rather than extensive ownership of cultivation or large-scale production infrastructure. Information regarding material international operations, major joint ventures, or large controlled production assets is limited. Data inconclusive based on available public sources regarding the scale of long-term manufacturing agreements or proprietary extraction technologies.

Strategic Position & Investments

CBD Life Sciences has positioned itself within the expanding consumer wellness and hemp-derived CBD market, emphasizing product diversification and brand visibility. Strategic initiatives referenced in company communications have included the expansion of online sales channels, development of additional CBD formulations, and broader consumer outreach efforts. The company has also discussed intentions to capitalize on increasing consumer acceptance of cannabinoid-based wellness products and regulatory shifts affecting hemp-derived products in the United States.

Public disclosures indicate that the company has pursued acquisitions and business combinations to support its transition into the CBD sector. LBC Bioscience Inc. has been referenced in prior corporate materials as part of the company’s operational and branding development efforts. However, independently verifiable details regarding the financial scale, operational integration, or long-term impact of these transactions remain limited. The company’s strategic focus appears centered on consumer wellness products rather than pharmaceutical cannabis development, large-scale cultivation, or regulated THC-focused operations.

Geographic Footprint

CBD Life Sciences is headquartered in the United States, with business activity primarily focused on the domestic CBD consumer products market. Public disclosures and OTC filings indicate that the company’s sales and marketing efforts are largely U.S.-oriented, particularly in states permitting hemp-derived CBD commerce under federal and state guidelines. The company’s operational model appears to rely heavily on online distribution and third-party fulfillment networks.

There is limited verifiable evidence of a significant physical operating presence outside the United States. While company communications have occasionally referenced broader market ambitions, independently confirmed information regarding sustained international operations, foreign subsidiaries, or material overseas investment activity remains limited. Data inconclusive based on available public sources regarding the company’s long-term international expansion footprint.

Leadership & Governance

CBD Life Sciences has undergone leadership and strategic restructuring as part of its transition into the CBD and wellness industry. Public corporate disclosures and OTC market materials identify executive leadership involved in overseeing product expansion, investor relations, and operational strategy. The company’s governance structure appears relatively small compared with larger publicly traded cannabis or consumer wellness firms.

Key executives publicly associated with the company include:

• Lisa Nelson – President and Chief Executive Officer
• Lisa Nelson – Director

Public statements from leadership have emphasized growth through product diversification, shareholder visibility, and participation in the expanding hemp-derived wellness sector. Information regarding a broader executive bench, independent board composition, or extensive institutional governance structures is limited in publicly available filings and disclosures.